Porcine recombinant factor VIII: an additional weapon to handle anti-factor VIII antibodies.

2017/07/01 by Pier Mannuccio Mannucci, Massimo Franchini · 1 citation
Medicine · #Hemophilia Treatment and Research #Hemostasis and retained surgical items #Blood Coagulation and Thrombosis Mechanisms

paper · doi:10.2450/2016.0030-16

openalex publication_date 2017/07/01 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/15

Abstract

This review focuses on the use of recombinant porcine factor VIII (FVIII) for the treatment of bleeding episodes in patients with severe haemophilia A complicated by inhibitors and in those with acquired haemophilia A due to the onset of anti-FVIII autoantibodies. We present the main characteristics of recombinant porcine factor VIII (FVIII) and provide a summary of the published results of the clinical studies of this novel recombinant FVIII. There is a special emphasis on how the use of recombinant porcine factor VIII (FVIII) is expected to improve the clinical management of these patients.

Citations

• Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice
• Acquired haemophilia A: A 2013 update

Cited by

• Haemophilia [wikipedia]

Related

• Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice
• Factor VIII inhibitors in hemophilia A: rationale and latest evidence
• Recombinant clotting factors
• Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia
• AAV5–Factor VIII Gene Transfer in Severe Hemophilia A